Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16355456 | 0.83 | CYP1A1 (0.37) | SCN10ACYP1A1CYP1A2CYP1B1SCN5A | |
| SCHEMBL16355448 | 0.80 | SCN10A (0.41) | SCN10ACYP1A2SCN5ANLN | |
| SCHEMBL20900024 | 0.78 | EGFR (0.46) | SCN10ASCN5ANLN | |
| SCHEMBL20900023 | 0.78 | EGFR (0.46) | SCN10ASCN5ANLN | |
| SCHEMBL19323265 | 0.78 | TRPV1 (0.44) | SCN10ASCN5ANLN | |
| SCHEMBL18480825 | 0.78 | MASP2 (0.55) | SSTR1 | |
| SCHEMBL20900140 | 0.78 | MASP2 (0.55) | SSTR1 | |
| SCHEMBL15113143 | 0.77 | SCN10A (0.40) | SCN10ASCN5ANLN | |
| SCHEMBL20054101 | 0.77 | SCN10A (0.40) | SCN10ASCN5ANLN | |
| Hydrochloric Acid SCHEMBL18438992 | 0.76 | MASP2 (0.53) | SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1L, HBS1L, HAVCR2 | SCN10A 4051/4885CYP1A1 713/4885CYP1A2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.